PF-06256142

Request For Quotation
PF-06256142 Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Beijing Solarbio Science & Tecnology Co., Ltd.  
Tel: 17801761073 18101056239
Email: 3193328036@qq.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com

PF-06256142 manufacturers

  • PF-06256142
  • PF-06256142 pictures
  • $1820.00
  • 2026-05-11
  • CAS:1609583-14-3
  • Purity:
  • Supply Ability: 10g
  • PF-06256142
  • PF-06256142 pictures
  • $1820.00
  • 2026-01-05
  • CAS:1609583-14-3
  • Purity:
  • Supply Ability: 10g
PF-06256142 Basic information
Product Name:PF-06256142
Synonyms:PF-06256142;PF 06256142,PF06256142;Imidazo[1,2-a]pyrazine, 5-[4-(furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl]-6-methyl-, (5S)-
CAS:1609583-14-3
MF:C21H16N4O2
MW:356.38
EINECS:
Product Categories:
Mol File:1609583-14-3.mol
PF-06256142 Structure
PF-06256142 Chemical Properties
density 1.34±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 200 mg/mL (514.88 mM; Need ultrasonic)
pka4.68±0.40(Predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
PF-06256142 Usage And Synthesis
UsesPF-06256142 is a potent, selective, CNS-penetrant and orally active agonist of the D1 receptor, with an EC50 and Ki of 33 nM and 12 nM, respectively. PF-06256142 has the potential for the research of schizophrenia and Parkinson's disease[1].
Biological ActivityPF-06256142 is a potent, selective, CNS-penetrant and orally active agonist of the D1 receptor, with an EC50 and Ki of 33 nM and 12 nM, respectively. PF-06256142 has the potential for the research of schizophrenia and Parkinson's disease[1]. PF-06256142 exhibits IC50 values of 10 μM)[1]. PF-06256142 exhibits high oral bioavailability (rat 85%) following oral administration (rat 5 mg/kg)[1].PF-06256142 exhibits terminal elimination half-life (rat 2.3 h) following intravenous administration (rat 5.0 mg/kg)[1].
in vivo

PF-06256142 exhibits high oral bioavailability (rat 85%) following oral administration (rat 5 mg/kg)[1].
PF-06256142 exhibits terminal elimination half-life (rat 2.3 h) following intravenous administration (rat 5.0 mg/kg)[1].

Animal Model:Rat[1]
Dosage:5.0 mg/kg for i.v.; 5 mg/kg for oral (Pharmacokinetic Analysis)
Administration:Intravenous injection and oral administration
Result:Oral bioavailability (85%), T1/2 (2.3 h).
IC 50Human D1 Receptor: 33 nM (EC50)
References[1]. Davoren JE, et al. Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization. J Med Chem. 2018 Nov 15.
PF-06256142 Preparation Products And Raw materials
Tag:PF-06256142(1609583-14-3) Related Product Information
Levodopa R-(-)-Apomorphine Creatine Sulpiride Thioridazine hydrochloride (-)-QUINPIROLE HYDROCHLORIDE